Immunomodulatory effects of galectin-1
in patients with chronic lymphocytic leukemia

Milos Kostic; Tanja Dzopalic; Goran Marjanovic; Ivana Urosevic; Ivana Milosevic

doi:10.5114/ceji.2021.105246

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

1/2021
vol. 46

Send email

Copy url:

abstract:

Clinical immunology

Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

Milos Kostic

¹

,

Tanja Dzopalic

¹

,

Goran Marjanovic

^{1, 2}

,

Ivana Urosevic

^{3, 4}

,

Ivana Milosevic

^{3, 4}

Department of Immunology, Medical Faculty of Nis, University of Nis, Nis, Serbia
Department of Hematology and Clinical Immunology, Clinical Centre Nis, Nis, Serbia
Department of Hematology, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Clinical Centre of Vojvodina, Hematology Clinic, Novi Sad, Serbia

Cent Eur J Immunol 2021; 46 (1): 54-62

DOI: https://doi.org/10.5114/ceji.2021.105246

Online publish date: 2021/04/18

View full text Get citation

PlumX metrics:

Galectin-1 (Gal-1) has been implicated in the progression of chronic lymphocytic leukemia (CLL) but also the development of immunodeficiency, which commonly accompany this malignancy. In this in vitro study, we investigated the effects of Gal-1 inhibition in the sera of immunocompromised CLL patients on immunomodulating properties of dendritic cells (DCs). DCs derived from peripheral blood mononuclear cells were treated with a healthy serum, CLL serum as well as the combination of CLL serum and Gal-1 inhibitor (OTX008). Following the treatment, the expression levels of DC maturation markers (CD80, CD83, CD86 and IDO-1) were determined as well as their cytokine profile and the ability to polarize the immune response in co-cultures with CD4+ T cells. After treatment with CLL serum, an increase in interleukin (IL)-10 production was observed in both DC cultures and co-cultures with CD4+ T cells. OTX008 caused a reduction in IL-10 production as well as IL-2, but no significant alteration in the expression of DC maturation markers or T regulatory cell (Treg) frequency was observed. The results of our study suggest that Gal-1 from CLL serum give rise to a specific IL-10+ CD4+ T cell phenotype, other than Treg, that could mediate immunodeficiency development in CLL patients.

keywords:

Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

Milos Kostic 1 , Tanja Dzopalic 1 , Goran Marjanovic 1, 2 , Ivana Urosevic 3, 4 , Ivana Milosevic 3, 4

galectin-1, immunodeficiency, chronic lymphocytic leukemia, OTX008, dendritic cell

Milos Kostic

¹

,

Tanja Dzopalic

¹

,

Goran Marjanovic

^{1, 2}

,

Ivana Urosevic

^{3, 4}

,

Ivana Milosevic

^{3, 4}